Antibody-Based Therapies

Ig-ABDEG is a first in class, Fc silenced IgG sweeping antibody designed to achieve rapid, deep, and sustained pan subclass IgG reduction while preserving a favorable safety profile. By combining high affinity IgG capture at physiological pH with release at endosomal pH and FcRn optimized trafficking, Ig-ABDEG enables efficient lysosomal clearance of all IgG subclasses without affecting other immunoglobulins, FcRn integrity, or albumin levels. This mechanistically differentiated approach supports chronic use in IgG mediated diseases, with a first in human study currently ongoing.

ANV200 was developed as Fc-engineered antibody with optimized FcγRIIIa and FcγRIIb engagement. It induces PD-1 agonism and drives ADCC against PD-1 pathogenic cells without disrupting PD-1/PD-L1 signaling. In PBMC and whole blood assays, ANV200 induced deeper depletion of activated PD-1⁺ T cells than benchmark antibodies and shifted the T-cell compartment toward naïve populations. In a xenogeneic GvHD model, ANV200 suppressed expansion of PD-1⁺ T cells, reduced disease progression, and provided complete protection from mortality, supporting ANV200's advancement into clinical development.

This presentation will provide a preview of key insights from Antibodies to Watch in 2027, including a review of antibody therapeutics first approved in 2026, those currently under regulatory review, and a projection of candidates likely to enter regulatory review by the end of 2027. The talk will also feature a focused analysis of emerging trends shaping the antibody therapeutics landscape, offering a data-driven perspective on innovation and pipeline evolution.

Multibodies introduce a new paradigm for multispecific biologics: a single Fab arm engineered to recognize two distinct antigens, enabling the full repertoire of bispecific functionality without requiring two different Fabs. This fundamentally expands the design space for multispecific antibodies unlocking novel binding topologies, programmable cooperativity, and architectures that can be simpler, more modular, and more manufacturable. The talk will outline how dual target single Fab recognition can multiply what is possible in therapeutic multispecific design.

Membrane proteins and receptors drive diseases such as cancer and autoimmune disorders. Rather than simply blocking them, selective degradation—including of previously “undruggable” receptors—can achieve deeper and more durable pathway inhibition. SureTAC (Surface Removal Targeting Chimeras) are bispecific antibodies that harness the endolysosomal system to degrade such membrane proteins by recruiting E3 ligases, enabling efficient target removal in vitro and in vivo. Laigo Bio is advancing the SureTAC platform to develop first-in-class therapies across oncology, inflammation, and autoimmune diseases.

This talk will showcase a novel antibody-based targeted protein degradation platform engineered to selectively eliminate pathogenic proteins in key immune pathways. It will discuss how this strategy can achieve deeper and more durable modulation of immune responses, with potential applications across multiple immunology indications.

EpiBiologic’s EpiTAC bispecific antibodies are a different therapeutic approach that can degrade receptor tyrosine kinases (RTKs) independent of their form. Removal of the oncogenic RTK and associated scaffolding function is differentiated from standard blocking approaches. Tissue-selective EpiTACs can degrade EGFR, cMET, and cKIT to drive deep, and prolonged anti-tumour activity independent of form. EpiTACs have the potential to redefine monotherapy and combination therapies. EPI-326 is a novel tissue selective EGFR approach that could address the limitations of current EGFR drugs. A phase I study of EPI-326 in patients with advanced/metastatic HNSCC and mutant EGFR NSCLC is ongoing.

DARPins are small, high-affinity protein scaffolds with promise as delivery vectors for targeted radiopharmaceutical cancer therapy. This presentation outlines preclinical strategies to advance radio-DARPin Therapeutics (RDT) toward clinical evaluation, focusing on enhanced tumour uptake and reduced kidney exposure. First patient images from compassionate care with MP0712, a DLL3-targeting 212Pb-based RDT, demonstrate selective uptake in primary and metastatic SCLC lesions, providing early clinical proof-of-concept for the RDT platform.

Carcinoembryonic antigen adhesion molecule 5 (CEACAM5) is overexpressed in a subset of patients with colorectal carcinomas, mucinous carcinomas of the ovary and breast, and small-cell lung carcinomas, with minimal expression in normal tissue. We have developed affibody molecules that specifically target CEACAM5-overexpressing tumors and loaded them with lutetium-177. Preclinical studies in mice showed that the constructs can be used to efficiently treat CEACAM5-overexpressing pancreatic tumors with minimal side effects.